Novo Financial Statements From 2010 to 2024

N1VO34 Stock  BRL 68.97  4.14  6.39%   
Novo Nordisk financial statements provide useful quarterly and yearly information to potential Novo Nordisk AS investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Novo Nordisk financial statements helps investors assess Novo Nordisk's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Novo Nordisk's valuation are summarized below:
Novo Nordisk AS does not presently have any fundamental ratios for analysis.
Check Novo Nordisk financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novo Nordisk's main balance sheet or income statement drivers, such as , as well as many indicators such as . Novo financial statements analysis is a perfect complement when working with Novo Nordisk Valuation or Volatility modules.
  
This module can also supplement various Novo Nordisk Technical models . Check out the analysis of Novo Nordisk Correlation against competitors.

Novo Nordisk AS Company Return On Equity Analysis

Novo Nordisk's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

 = 

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Novo Nordisk Return On Equity

    
  0.72  
Most of Novo Nordisk's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novo Nordisk AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Competition

Based on the latest financial disclosure, Novo Nordisk AS has a Return On Equity of 0.72. This is 103.0% lower than that of the Healthcare sector and 101.97% lower than that of the Biotechnology industry. The return on equity for all Brazil stocks is notably lower than that of the firm.

Novo Nordisk AS Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Novo Nordisk's current stock value. Our valuation model uses many indicators to compare Novo Nordisk value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novo Nordisk competition to find correlations between indicators driving Novo Nordisk's intrinsic value. More Info.
Novo Nordisk AS is regarded fifth in return on equity category among its peers. It also is regarded fifth in return on asset category among its peers reporting about  0.30  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novo Nordisk AS is roughly  3.32 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Novo Nordisk by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Novo Nordisk's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Novo Nordisk Financial Statements

Novo Nordisk stakeholders use historical fundamental indicators, such as Novo Nordisk's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novo Nordisk investors may analyze each financial statement separately, they are all interrelated. For example, changes in Novo Nordisk's assets and liabilities are reflected in the revenues and expenses on Novo Nordisk's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Novo Nordisk AS. Please read more on our technical analysis and fundamental analysis pages.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Novo Stock

When determining whether Novo Nordisk AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Novo Nordisk's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Novo Nordisk As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Novo Nordisk As Stock:
Check out the analysis of Novo Nordisk Correlation against competitors.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.